Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate‐risk acute myeloid leukemia in first complete remission undergoing auto‐HSCT: An open‐label, multicenter, randomized phase 3 trial
Sign Up to like & getrecommendations! Published in 2023 at "American Journal of Hematology"
DOI: 10.1002/ajh.26800
Abstract: We report a randomized prospective phase 3 study, designed to evaluate the efficacy and tolerability of idarubicin plus busulfan and cyclophosphamide (IDA‐BuCy) versus BuCy in autologous hematopoietic stem‐cell transplantation (auto‐HSCT) for intermediate‐risk acute myeloid leukemia… read more here.
Keywords: ida bucy; bucy; auto hsct;